|
|
|
|
|
|
| Dr Youssef Bennani, a speaker at the marcus evans Discovery Summit 2012, on developing innovative drugs. |
London, Mar 21, 2012 - (ACN Newswire) - Pharmaceutical companies need to ask themselves whether they are truly innovating and adding value, or doing a lot of "Me Too" type of work, says Dr Youssef Bennani, Vice President Research & Development (R&D), Vertex Pharmaceuticals (Canada). The bloated cost of clinical development is largely due to the "Me Too" concept, he adds.
A speaker at the marcus evans Discovery Summit 2012, in Cannes, France, 22 - 23 March, Bennani offers his expertise into drug discovery and adding value to R&D programmes.
- How can pharmaceutical companies add value to R&D programmes?
Pharmaceutical companies need to focus on the real priorities - innovation in disease control and treatment, instead of endeavouring in a lot of "Me Too" work. A focus on real patient needs, rather than meeting financial goals is mandatory.
- Why is this an issue in this industry?
The pressure to bring in revenue is common in all businesses, but the pharmaceutical industry has gone to the extreme of absolutely matching marketing expectations to the detriment of what is necessary for the patient. Decisions are based on guarding market share and generating revenue, rather than on better disease treatments. Adjusting the thinking within the industry would lead to better, as well as, differentiated products.
- How would this impact the cost of drug development?
The bloated cost of clinical development is largely due to the concept of repetition. For second or third generation products, regulators demand large trials to show differentiation or non-inferiority, making drug development costly. Trials of brand new drugs should cost less. Stratification with regards to genotyping patients (selecting who is more likely to respond) and personalised medicine would go a long way to reduce costs.
On the discovery front, if times were shortened, the cost of researching would obviously go down. However, the cost of drug discovery is far inferior to that of clinical development, on a programme basis. Efforts in saving from the larger part and speeding it up would make a bigger difference.
- What are some of the scientific areas worth following?
A much greater investment and understanding of predictive toxicology on all fronts is needed. In the past, drugs failed due to our inability to predict pharmacokinetics and toxicology in human settings. We have come a long way in pharmacokinetics but not yet mastered the science of toxicology.
Predictive pharmacology is another area that has not yet panned out. Many molecules work in animal models of disease, but fail in the clinic. The link between discovery and clinical pharmacology should be further researched.
About the Discovery Summit 2012
This unique forum will take place at the Majestic Barriere Hotel, Cannes, France, 22 - 23 March 2012.
Offering much more than any conference, exhibition or trade show, this exclusive meeting will bring together esteemed industry thought leaders and solution providers to a highly focused and interactive networking event. The Summit includes presentations on ensuring successful drug discovery, stimulating innovation and creating partnerships.
For more information please send an email to info@marcusevanscy.com or visit the event website at www.discovery-summit.com/RiccardoIsolaInterview
The Pharma Network - marcus evans Summits group delivers peer-to-peer information on strategic matters, professional trends and breakthrough innovations.
LinkedIn: www.linkedin.com/groups?gid=3529112&trk=myg_ugrp_ovr
YouTube: www.youtube.com/user/MarcusEvansPharma
Twitter: www.twitter.com/meSummitsPharma
SlideShare: www.slideshare.net/MarcusEvansPharma
marcus evans group - life sciences / pharma sector portal: http://tiny.cc/1OCf2b
Please note that the Summit is a closed business event and the number of participants strictly limited.
Contact:
Sarin Kouyoumdjian-Gurunlian
Press Manager,
marcus evans Summits
Tel: +357-22-849313
Email: press@marcusevanscy.com
Topic: Press release summary
Source: marcus evans Summits
Sectors: Science & Research, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| marcus evans Summits |
| Jan 5, 2016 15:31 HKT/SGT |
|
How the Right Interior Design Can Lead to an Unforgettable Hotel Experience |
| Jan 5, 2016 14:53 HKT/SGT |
|
Why Hotels Need to Invest in Technology |
| Jan 5, 2016 14:15 HKT/SGT |
|
Why Defence Organisations Should Reconsider Their Talent Management Approach |
| Oct 23, 2015 03:00 HKT/SGT |
|
How to Distinguish the Right Emerging Markets to Invest in |
| Oct 22, 2015 21:20 HKT/SGT |
|
How to Design a Solid Privacy and Data Protection Programme |
| Oct 22, 2015 21:00 HKT/SGT |
|
The Wellness Model: A Business Strategy to Reduce Healthcare Costs |
| Oct 17, 2015 02:20 HKT/SGT |
|
The Changing Dynamics of the Oil Market |
| Oct 17, 2015 02:10 HKT/SGT |
|
How China's Slowdown Affects Global Investors |
| Oct 17, 2015 02:00 HKT/SGT |
|
How to Use Globalisation as a Marketing Tool |
| Sept 30, 2015 07:30 HKT/SGT |
|
The Need for Holistic Revenue Cycle Management Models |
| More news >> |
 |
|
|
|
